372 related articles for article (PubMed ID: 25117182)
41. Soluble receptor-binding cancer antigen expressed on SiSo cells in pleural fluid: a potential diagnostic marker for malignant pleural effusion.
Aoe K; Hiraki A; Maeda T; Murakami T; Yamazaki K; Sugi K; Takeyama H
Chest; 2004 Oct; 126(4):1195-7. PubMed ID: 15486382
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of two strategies for the interpretation of tumour markers in pleural effusions.
Trapé J; Sant F; Franquesa J; Montesinos J; Arnau A; Sala M; Bernadich O; Martín E; Perich D; Pérez C; Lopez J; Ros S; Esteve E; Pérez R; Aligué J; Gurt G; Catot S; Domenech M; Bosch J; Badal JM; Bonet M; Molina R; Ordeig J
Respir Res; 2017 May; 18(1):103. PubMed ID: 28545517
[TBL] [Abstract][Full Text] [Related]
43. Differences in
Xie T; Wang Q; Gao J; He K; Yu J
Ann Clin Lab Sci; 2024 Mar; 54(2):201-210. PubMed ID: 38802158
[TBL] [Abstract][Full Text] [Related]
44. Pleural cancer antigen-125 levels in benign and malignant pleural effusions.
Choi WI; Qama D; Lee MY; Kwon KY
Int J Tuberc Lung Dis; 2013 May; 17(5):693-7. PubMed ID: 23575338
[TBL] [Abstract][Full Text] [Related]
45. Diagnostic and prognostic significance of survivin levels in malignant pleural effusion.
Görgün D; Seçik F; Midilli K; Akkaya V; Yıldız P
Respir Med; 2013 Aug; 107(8):1260-5. PubMed ID: 23791464
[TBL] [Abstract][Full Text] [Related]
46. LC-MS-based serum metabolic profiling for genitourinary cancer classification and cancer type-specific biomarker discovery.
Lin L; Huang Z; Gao Y; Chen Y; Hang W; Xing J; Yan X
Proteomics; 2012 Aug; 12(14):2238-46. PubMed ID: 22685041
[TBL] [Abstract][Full Text] [Related]
47. Pentraxin-3: A novel biomarker for discriminating parapneumonic from other exudative effusions.
Ozsu S; Abul Y; Mentese A; Bektas H; Uzun A; Ozlu T; Porcel JM
Respirology; 2013 May; 18(4):657-62. PubMed ID: 23286371
[TBL] [Abstract][Full Text] [Related]
48. Serum metabolic profiling study of lung cancer using ultra high performance liquid chromatography/quadrupole time-of-flight mass spectrometry.
Li Y; Song X; Zhao X; Zou L; Xu G
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Sep; 966():147-53. PubMed ID: 24856296
[TBL] [Abstract][Full Text] [Related]
49. Vascular endothelial growth factor in pleural fluid for differential diagnosis of benign and malignant origin and its clinical applications.
Fiorelli A; Vicidomini G; Di Domenico M; Napolitano F; Messina G; Morgillo F; Ciardiello F; Santini M
Interact Cardiovasc Thorac Surg; 2011 Mar; 12(3):420-4. PubMed ID: 21172937
[TBL] [Abstract][Full Text] [Related]
50. Performance of CEA and CA19-9 in identifying pleural effusions caused by specific malignancies.
Hackbarth JS; Murata K; Reilly WM; Algeciras-Schimnich A
Clin Biochem; 2010 Sep; 43(13-14):1051-5. PubMed ID: 20529669
[TBL] [Abstract][Full Text] [Related]
51. Metabolomic Profiling of Plasma from Patients with Tuberculosis by Use of Untargeted Mass Spectrometry Reveals Novel Biomarkers for Diagnosis.
Lau SK; Lee KC; Curreem SO; Chow WN; To KK; Hung IF; Ho DT; Sridhar S; Li IW; Ding VS; Koo EW; Wong CF; Tam S; Lam CW; Yuen KY; Woo PC
J Clin Microbiol; 2015 Dec; 53(12):3750-9. PubMed ID: 26378277
[TBL] [Abstract][Full Text] [Related]
52. Reactive oxygen species modulator 1 (Romo1) as a novel diagnostic marker for lung cancer-related malignant effusion.
Lee SH; Park MJ; Choi SI; Lee EJ; Lee SY; In KH
Medicine (Baltimore); 2017 Jan; 96(4):e5975. PubMed ID: 28121949
[TBL] [Abstract][Full Text] [Related]
53. [Diagnostic value of DNA, RNA and proliferating cell nuclear antigen examination in malignant pleural effusions by flow cytometry].
Wang LX; Chen WX; Wu J; Chen SX; Huang XY; Chen YF
Zhonghua Jie He He Hu Xi Za Zhi; 2006 Dec; 29(12):804-7. PubMed ID: 17327081
[TBL] [Abstract][Full Text] [Related]
54. The diagnostic significance of the detection of cytokeratin 19 mRNA by quantitative RT-PCR in benign and malignant pleural effusions.
Xu F; Chen J; Shen HH; Wang XD; Shan J
J Zhejiang Univ Sci; 2004 Oct; 5(10):1286-9. PubMed ID: 15362202
[TBL] [Abstract][Full Text] [Related]
55. Immunocytochemistry and ELISA quantitation of mucin for diagnosis of malignant pleural effusions.
Yang PC; Luh KT; Kuo SH; Wu CW
Am Rev Respir Dis; 1992 Dec; 146(6):1571-5. PubMed ID: 1456577
[TBL] [Abstract][Full Text] [Related]
56. Pressurized CEC coupled with QTOF-MS for urinary metabolomics.
Wu Q; Yu X; Wang Y; Gu X; Ma X; Lv W; Chen Z; Yan C
Electrophoresis; 2014 Sep; 35(17):2470-8. PubMed ID: 24789083
[TBL] [Abstract][Full Text] [Related]
57. [Diagnostic value of the combined determination of carcinoembryonic antigen (CEA) in pleural effusion and serum with an enzyme immunoassay (EIA). Sensitivity, specificity and relation to tumor type].
Klech H; Rona G; Hutter C; Bayer PM; Kummer F
Wien Klin Wochenschr; 1986 Sep; 98(17):564-73. PubMed ID: 3020811
[TBL] [Abstract][Full Text] [Related]
58. Th1 and Th2 cytokine profiles in malignant pleural effusion.
Ghayumi MA; Mojtahedi Z; Fattahi MJ
Iran J Immunol; 2011 Dec; 8(4):195-200. PubMed ID: 22201616
[TBL] [Abstract][Full Text] [Related]
59. Differentiating tuberculous from malignant pleural effusions: a scoring model.
Porcel JM; Vives M
Med Sci Monit; 2003 May; 9(5):CR175-80. PubMed ID: 12761453
[TBL] [Abstract][Full Text] [Related]
60. Proteome screening of pleural effusions identifies IL1A as a diagnostic biomarker for non-small cell lung cancer.
Li Y; Lian H; Jia Q; Wan Y
Biochem Biophys Res Commun; 2015 Feb; 457(2):177-82. PubMed ID: 25554695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
